T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,570,774 shares of Nurix Therapeutics Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates reported holding 4,570,774 shares of Nurix Therapeutics common stock, representing 4.4% of the class.
- Sole voting power: The filing disclosed sole voting power over 4,422,815 shares.
- Sole dispositive power: T. Rowe Price reported sole dispositive power over all 4,570,774 shares.
- No shared power: Both shared voting power and shared dispositive power were reported as 0.
- Event date: The date of the event requiring this filing was stated as September 30, 2026.
- Filer classification: T. Rowe Price Associates is identified as an investment adviser (type IA), incorporated in Maryland.
T. Rowe Price Associates Amends Beneficial Ownership Position in Nurix Therapeutics
T. Rowe Price Associates, Inc., a Maryland-incorporated investment adviser headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 1 to its Schedule 13G regarding common stock of Nurix Therapeutics Inc. (NASDAQ:NRIX). According to the filing, the triggering event date was September 30, 2026, and the statement was signed by Ellen York, Vice President, on November 16, 2026.
The filing reported aggregate beneficial ownership of 4,570,774 shares, equating to 4.4% of the outstanding class of Nurix Therapeutics common stock (CUSIP 67080M103). T. Rowe Price disclosed sole voting power over 4,422,815 shares and sole dispositive power over the full 4,570,774 shares. The filing reported zero shared voting or dispositive power with any other party.
The amended filing noted ownership of 5 percent or less of the class, satisfying the threshold disclosure under Item 5 of Schedule 13G. The certification included in the filing states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." T. Rowe Price also declared that "the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
What Was Disclosed
T. Rowe Price Associates, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 4,570,774 shares, or 4.4%, of Nurix Therapeutics Inc. common stock as of September 30, 2026, with sole voting power over 4,422,815 shares and no shared voting or dispositive power.




Please wait processing your request...